🟢 [E5187] Longevity and AI-driven drug discovery creating new healthcare paradigm. AI agents discovering drugs independently; longevity becomes massive bullish macro theme. Healthcare spending reduction possible through prevention/longevity.

🟢 [E5184] Fortune 500 incumbents face extinction as AI agents disrupt business models and competitive advantages. Inference switch and reasoning switch accelerate adoption; AI creates new competitors faster than incumbents can adapt.

🟢 [E5185] Robotics and humanoids represent next wave of market disruption beyond software. Figure AI raising $1.5B at 15x valuation jump; multiple robotics companies showing tangible progress. Embodied AI becomes massive market opportunity.

🟢 [E5188] Portfolio must shift from Fortune 500 incumbents to AI-driven growth plays and robotics. Incumbents face structural margin pressure; new entrants leveraging AI agents capture market share. Allocation toward disruptors and away from legacy assets.

🟢 [E5186] Sentiment bottoming creates inflection point for broader AI adoption. As uncertainty clears and technology maturity increases, deployment accelerates. Financials and JP Morgan signaling more optimism on AI adoption and margin expansion.